Clovis Oncology, Inc. (CLVS)

Oncology Corporate Profile

Stock Performance

14.1600
-0.2300

HQ Location

2525 28th Street, Suite 100
Boulder, CO 80301

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

Website: http://www.clovisoncology.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
rucaparibPARP inhibitor (oral)Ovarian cancerIII
rucaparibPARP inhibitor (oral)Prostate cancerIII
rucaparibPARP inhibitor (oral)Breast cancerII
lucitanibtyrosine kinase inhibitorBreast cancerIIServier
rucaparibPARP inhibitor (oral)Gastric cancerII
rucaparibPARP inhibitor (oral)Ovarian cancerII
rucaparibPARP inhibitor (oral)Prostate cancerII
rucaparibPARP inhibitor (oral)Triple negative Breast cancerII
lucitanib (+ fulvestrant)tyrosine kinase inhibitorBreast cancerIServier

View additional information on product candidates here »

Pipeline image

Source


http://www.clovisoncology.com/

Recent News Headlines

Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer

3/12/2017 02:03 pm

[Business Wire] - Clovis Oncology, Inc. announced new data from parts 1 and 2 of the ongoing ARIEL2 Phase 2 study being presented today at the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in National Harbor, MD.

Clovis reports 4Q loss

2/22/2017 10:00 pm

Clovis reports 4Q loss

2/22/2017 10:00 pm

Clovis Oncology Announces 2016 Operating Results

2/22/2017 09:00 pm

[Business Wire] - Clovis Oncology, Inc. reported financial results for the quarter and year ended December 31, 2016, and provided an update on the Company’s clinical development programs and regulatory outlook for 2017.